Michael J. Birrer, MD of Massachusetts General Hospital discusses ovarian cancer is targetable with PARP inhibitors at SGO 2016.
Because because ovarian cancer has this defect in DNA repair. And you see this sort of gross shifting of DNA. How chromosomal abnormalities it has been argued that this tumors not target herbal. And the truth is that it is. You can target the DNA repair process very effectively I think with part innovators and maybe apartment either combinations. And then to the low frequency mutations which do exist but the low frequency once we understand the biology better. It's likely from my viewpoint. That will be able to conduct rational trials even even target those events. And help patients.